Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3680 Plus ADT vs Placebo Plus ADT in High-Risk Localized or Locally Advanced Prostate Cancer
NCT05009290Phase 3Terminated
- Sponsor
- Hengrui
- Start
- Nov 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rezvilutamide in prostate cancer (PCa), sponsored by Hengrui. Started Nov 2021; status: terminated.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05009290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009290.